Maria P Abbracchio

List of Publications by Year in Descending Order

198 papers	12,102 citations	55 h-index	105 g-index
205 ext. papers	13,255 ext. citations	6.1 avg, IF	6.05 L-index

#	Paper	IF	Citations
198	Novel Experimental Approaches to Study Myelination and Remyelination in the Central Nervous System. *Frontiers in Cellular Neuroscience*, **2021**, 15, 748849	6.1	3
197	Functional genomic analyses highlight a shift in Gpr17-regulated cellular processes in oligodendrocyte progenitor cells and underlying myelin dysregulation in the aged mouse cerebrum. *Aging Cell*, **2021**, 20, e13335	9.9	10
196	The Distribution of GPR17-Expressing Cells Correlates with White Matter Inflammation Status in Brain Tissues of Multiple Sclerosis Patients. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
195	Perspectives on Geoff Burnstock as researcher, teacher and friend. *Biochemical Pharmacology*, **2021** , 187, 114395	6	2
194	Pathway-Focused Profiling of Oligodendrocytes Over-Expressing miR-125a-3p Reveals Alteration of Wnt and Cell-to-Cell Signaling. *Cellular and Molecular Neurobiology*, **2021**, 41, 105-114	4.6	1
193	The history of the Purine Club: a tribute to Prof. Geoffrey Burnstock. *Purinergic Signalling*, **2021**, 17, 127-134	3.3	2
192	Microglial vesicles improve post-stroke recovery by preventing immune cell senescence and favoring oligodendrogenesis. *Molecular Therapy*, **2021**, 29, 1439-1458	11.7	13
191	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. *British Journal of Pharmacology*, **2021**, 178 Suppl 1, S27-S156	8.6	46
190	In vivo silencing of miR-125a-3p promotes myelin repair in models of white matter demyelination. *Glia*, **2020**, 68, 2001-2014	9	14
189	Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging. *Neurobiology of Aging*, **2020**, 89, 12-23	5.6	6
188	Regulation and signaling of the GPR17 receptor in oligodendroglial cells. *Glia*, **2020**, 68, 1957-1967	9	12
187	Adenosine Signaling in Glioma Cells. *Advances in Experimental Medicine and Biology*, **2020**, 1202, 13-33	3.6	8
186	Prenatal Stress Impairs Spinal Cord Oligodendrocyte Maturation via BDNF Signaling in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis. *Cellular and Molecular Neurobiology*, **2020**, 1	4.6	1
185	In Memoriam Geoffrey Burnstock: Creator of Purinergic Signaling. *Function*, **2020**, 1,	6.1	15
184	Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis. *PLoS ONE*, **2020**, 15, e0231483	3.7	9
183	Abnormal Upregulation of GPR17 Receptor Contributes to Oligodendrocyte Dysfunction in SOD1 G93A Mice. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	16
182	Purinergic Receptors on Oligodendrocyte Progenitors: Promising Targets for Myelin Repair in Multiple Sclerosis?. *Frontiers in Pharmacology*, **2020**, 11, 629618	5.6	1

181	Improvement of fiber connectivity and functional recovery after stroke by montelukast, an available and safe anti-asthmatic drug. *Pharmacological Research*, **2019**, 142, 223-236	10.2	22
180	Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure. *Acta Neuropathologica*, **2019**, 138, 987-1012	14.3	67
179	Basal astrocyte and microglia activation in the central nervous system of Familial Hemiplegic Migraine Type I mice. *Cephalalgia*, **2019**, 39, 1809-1817	6.1	11
178	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. *British Journal of Pharmacology*, **2019**, 176 Suppl 1, S21-S141	8.6	391
177	P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. *IUPHAR/BPS Guide To Pharmacology CITE*, **2019**, 2019,	1.7	5
176	Surface Plasmon Resonance as a Tool for Ligand Binding Investigation of Engineered GPR17 Receptor, a G Protein Coupled Receptor Involved in Myelination. *Frontiers in Chemistry*, **2019**, 7, 910	5	11
175	Differential local tissue permissiveness influences the final fate of GPR17-expressing oligodendrocyte precursors in two distinct models of demyelination. *Glia*, **2018**, 66, 1118-1130	9	29
174	Steps towards Collective Sustainability in Biomedical Research. *Trends in Molecular Medicine*, **2018**, 24, 429-432	11.5	6
173	Purple Corn Extract as Anti-allodynic Treatment for Trigeminal Pain: Role of Microglia. *Frontiers in Cellular Neuroscience*, **2018**, 12, 378	6.1	19
172	The role of oligodendrocyte precursor cells expressing the GPR17 receptor in brain remodeling after stroke. *Cell Death and Disease*, **2017**, 8, e2871	9.8	44
171	Pharmacological Properties and Biological Functions of the GPR17 Receptor, a Potential Target for Neuro-Regenerative Medicine. *Advances in Experimental Medicine and Biology*, **2017**, 1051, 169-192	3.6	19
170	Pathophysiological Role of Purines and Pyrimidines in Neurodevelopment: Unveiling New Pharmacological Approaches to Congenital Brain Diseases. *Frontiers in Pharmacology*, **2017**, 8, 941	5.6	45
169	A new role for the P2Y-like GPR17 receptor in the modulation of multipotency of oligodendrocyte precursor cells in vitro. *Purinergic Signalling*, **2016**, 12, 661-672	3.8	12
168	MiR-125a-3p timely inhibits oligodendroglial maturation and is pathologically up-regulated in human multiple sclerosis. *Scientific Reports*, **2016**, 6, 34503	4.9	34
167	GPR17 expressing NG2-Glia: Oligodendrocyte progenitors serving as a reserve pool after injury. *Glia* , **2016**, 64, 287-99	9	55
166	A promiscuous recognition mechanism between GPR17 and SDF-1: Molecular insights. *Cellular Signalling*, **2016**, 28, 631-42	4.9	9
165	CNS remyelination as a novel reparative approach to neurodegenerative diseases: The roles of purinergic signaling and the P2Y-like receptor GPR17. *Neuropharmacology*, **2016**, 104, 82-93	5.5	48
164	Intertwining extracellular nucleotides and their receptors with Ca2+ in determining adult neural stem cell survival, proliferation and final fate. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2016**, 371,	5.8	9

163	SNX27, a protein involved in down syndrome, regulates GPR17 trafficking and oligodendrocyte differentiation. *Glia*, **2016**, 64, 1437-60	9	14
162	Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. *Nature Communications*, **2015**, 6, 8466	17.4	101
161	Early phenotypic asymmetry of sister oligodendrocyte progenitor cells after mitosis and its modulation by aging and extrinsic factors. *Glia*, **2015**, 63, 271-86	9	37
160	The ubiquitin ligase Mdm2 controls oligodendrocyte maturation by intertwining mTOR with G protein-coupled receptor kinase 2 in the regulation of GPR17 receptor desensitization. *Glia*, **2015**, 63, 2327-39	9	36
159	P2Y2 receptor antagonists as anti-allodynic agents in acute and sub-chronic trigeminal sensitization: role of satellite glial cells. *Glia*, **2015**, 63, 1256-69	9	50
158	Purines regulate adult brain subventricular zone cell functions: contribution of reactive astrocytes. *Glia*, **2014**, 62, 428-39	9	29
157	Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor. *Journal of Cerebral Blood Flow and Metabolism*, **2014**, 34, 979-88	7.3	58
156	Biochemical and immunological aspects of protein aggregation in neurodegenerative diseases. *Journal of the Iranian Chemical Society*, **2014**, 11, 1503-1512	2	1
155	Nonprofit foundations spur translational research. *Trends in Pharmacological Sciences*, **2014**, 35, 552-5	13.2	9
154	Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review. *Autoimmunity*, **2014**, 47, 287-306	3	13
153	Oxysterols act as promiscuous ligands of class-A GPCRs: in silico molecular modeling and in vitro validation. *Cellular Signalling*, **2014**, 26, 2614-20	4.9	27
152	Ventral tegmental area/substantia nigra and prefrontal cortex rodent organotypic brain slices as an integrated model to study the cellular changes induced by oxygen/glucose deprivation and reperfusion: effect of neuroprotective agents. *Neurochemistry International*, **2014**, 66, 43-54	4.4	4
151	A rapid and efficient immunoenzymatic assay to detect receptor protein interactions: G protein-coupled receptors. *International Journal of Molecular Sciences*, **2014**, 15, 6252-64	6.3	12
150	Expression of dual nucleotides/cysteinyl-leukotrienes receptor GPR17 in early trafficking of cardiac stromal cells after myocardial infarction. *Journal of Cellular and Molecular Medicine*, **2014**, 18, 1785-96	5.6	15
149	Does GRK-□arrestin machinery work as a "switch on" for GPR17-mediated activation of intracellular signaling pathways?. *Cellular Signalling*, **2014**, 26, 1310-25	4.9	32
148	Changes of the GPR17 receptor, a new target for neurorepair, in neurons and glial cells in patients with traumatic brain injury. *Purinergic Signalling*, **2013**, 9, 451-62	3.8	45
147	UDP-glucose enhances outward K(+) currents necessary for cell differentiation and stimulates cell migration by activating the GPR17 receptor in oligodendrocyte precursors. *Glia*, **2013**, 61, 1155-71	9	45
146	Adenosine signaling in glioma cells. *Advances in Experimental Medicine and Biology*, **2013**, 986, 13-30	3.6	11

145	Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study. *International Journal of Molecular Sciences*, **2013**, 14, 2258-81	6.3	21
144	The regulated expression, intracellular trafficking, and membrane recycling of the P2Y-like receptor GPR17 in Oli-neu oligodendroglial cells. *Journal of Biological Chemistry*, **2013**, 288, 5241-56	5.4	31
143	Cardiomyocyte death induced by ischaemic/hypoxic stress is differentially affected by distinct purinergic P2 receptors. *Journal of Cellular and Molecular Medicine*, **2012**, 16, 1074-84	5.6	19
142	Extrinsic purinergic regulation of neural stem/progenitor cells: implications for CNS development and repair. *Stem Cell Reviews and Reports*, **2012**, 8, 755-67	6.4	56
141	Purinergic trophic signalling in glial cells: functional effects and modulation of cell proliferation, differentiation, and death. *Purinergic Signalling*, **2012**, 8, 539-57	3.8	32
140	Calcitonin gene-related peptide-mediated enhancement of purinergic neuron/glia communication by the algogenic factor bradykinin in mouse trigeminal ganglia from wild-type and R192Q Cav2.1 Knock-in mice: implications for basic mechanisms of migraine pain. *Journal of Neuroscience*, **2011**,	6.6	101
139	Oxygen-glucose deprivation increases the enzymatic activity and the microvesicle-mediated release of ectonucleotidases in the cells composing the blood-brain barrier. *Neurochemistry International*, **2011**, 59, 259-71	4.4	40
138	Purinergic signalling: from normal behaviour to pathological brain function. *Progress in Neurobiology*, **2011**, 95, 229-74	10.9	308
137	Role of purinergic signalling in neuro-immune cells and adult neural progenitors. *Frontiers in Bioscience - Landmark*, **2011**, 16, 2326-41	2.8	30
136	In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. *Journal of Computer-Aided Molecular Design*, **2011**, 25, 743-52	4.2	45
135	Expression of the new P2Y-like receptor GPR17 during oligodendrocyte precursor cell maturation regulates sensitivity to ATP-induced death. *Glia*, **2011**, 59, 363-78	9	48
134	The GPR17 receptor in NG2 expressing cells: focus on in vivo cell maturation and participation in acute trauma and chronic damage. *Glia*, **2011**, 59, 1958-73	9	83
133	Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1. *Analytical Biochemistry*, **2011**, 414, 300-2	3.1	11
132	Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation. *Journal of Biological Chemistry*, **2011**, 286, 10593-604	5.4	128
131	Agonist-induced desensitization/resensitization of human G protein-coupled receptor 17: a functional cross-talk between purinergic and cysteinyl-leukotriene ligands. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 338, 559-67	4.7	25
130	Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. *Haematologica*, **2011**, 96, 937-42	6.6	52
129	Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. *Journal of Medicinal Chemistry*, **2010**, 53, 3489-501	8.3	51
128	Expression and contribution of satellite glial cells purinoceptors to pain transmission in sensory ganglia: an update. *Neuron Glia Biology*, **2010**, 6, 31-42		49

127	Temporomandibular joint inflammation activates glial and immune cells in both the trigeminal ganglia and in the spinal trigeminal nucleus. *Molecular Pain*, **2010**, 6, 89	3.4	78
126	International meeting "Purines 2010: adenosine nucleosides and nucleotides in biomedicine". *Purinergic Signalling*, **2010**, 6, 293-6	3.8	
125	Regulation of PC12 cell survival and differentiation by the new P2Y-like receptor GPR17. *Cellular Signalling*, **2010**, 22, 697-706	4.9	38
124	Forced unbinding of GPR17 ligands from wild type and R255I mutant receptor models through a computational approach. *BMC Structural Biology*, **2010**, 10, 8	2.7	25
123	Functional characterization of two isoforms of the P2Y-like receptor GPR17: [35S]GTPgammaS binding and electrophysiological studies in 1321N1 cells. *American Journal of Physiology - Cell Physiology*, **2009**, 297, C1028-40	5.4	44
122	Different properties of P2X(7) receptor in hippocampal and cortical astrocytes. *Purinergic Signalling* , **2009**, 5, 233-40	3.8	31
121	Development of an immobilized GPR17 receptor stationary phase for binding determination using frontal affinity chromatography coupled to mass spectrometry. *Analytical Biochemistry*, **2009**, 384, 123-9	3.1	44
120	The expanding field of purinergic signalling. *Trends in Neurosciences*, **2009**, 32, 1	13.3	5
119	Purinergic signalling in the nervous system: an overview. *Trends in Neurosciences*, **2009**, 32, 19-29	13.3	630
118	Purinergic signalling in inflammation of the central nervous system. *Trends in Neurosciences*, **2009**, 32, 79-87	13.3	168
117	The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. *Brain*, **2009**, 132, 2206-18	11.2	89
116	Biosimilars and safety issues. *Leukemia and Lymphoma*, **2009**, 50, 656-8	1.9	3
115	GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors. *BMC Bioinformatics*, **2008**, 9, 263	3.6	42
114	Purinoceptor-mediated calcium signaling in primary neuron-glia trigeminal cultures. *Cell Calcium*, **2008**, 43, 576-90	4	69
113	Opposite effects of uracil and adenine nucleotides on the survival of murine cardiomyocytes. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 522-36	5.6	10
112	Deorphanisation of G protein-coupled receptors: A tool to provide new insights in nervous system pathophysiology and new targets for psycho-active drugs. *Neurochemistry International*, **2008**, 52, 339-51	4.4	15
111	Using peripheral blood mononuclear cells to determine proteome profiles in human cardiac failure. *European Journal of Heart Failure*, **2008**, 10, 749-57	12.3	5
110	Short-term TNF-Alpha treatment induced A2B adenosine receptor desensitization in human astroglial cells. *Journal of Cellular Biochemistry*, **2008**, 104, 150-61	4.7	16

109	The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. *PLoS ONE*, **2008**, 3, e3579	3.7	167
108	Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington disease stages. *Neurobiology of Disease*, **2007**, 27, 36-43	7.5	33
107	A(2b) receptor mediates adenosine inhibition of taurine efflux from pituicytes. *Biology of the Cell*, **2007**, 99, 445-54	3.5	12
106	P1 receptors and cytokine secretion. *Purinergic Signalling*, **2007**, 3, 13-25	3.8	50
105	Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington disease. *Progress in Neurobiology*, **2007**, 81, 331-48	10.9	94
104	Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. *Neurobiology of Disease*, **2006**, 23, 44-53	7.5	68
103	Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 319, 1424-34	4.7	13
102	International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacological Reviews*, **2006**, 58, 281-341	22.5	996
101	A role for P2X7 in microglial proliferation. *Journal of Neurochemistry*, **2006**, 99, 745-58	6	113
100	The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. *EMBO Journal*, **2006**, 25, 4615-27	13	341
99	Roles of P2 receptors in glial cells: focus on astrocytes. *Purinergic Signalling*, **2006**, 2, 595-604	3.8	78
98	Pathophysiological roles of P2 receptors in glial cells. *Novartis Foundation Symposium*, **2006**, 276, 91-103; discussion 103-12, 275-81		24
97	Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia. *Brain Research Reviews*, **2005**, 48, 144-56		129
96	P2 receptors in human heart: upregulation of P2X6 in patients undergoing heart transplantation, interaction with TNFalpha and potential role in myocardial cell death. *Journal of Molecular and Cellular Cardiology*, **2005**, 39, 929-39	5.8	41
95	The recently deorphanized GPR80 (GPR99) proposed to be the P2Y15 receptor is not a genuine P2Y receptor. *Trends in Pharmacological Sciences*, **2005**, 26, 8-9	13.2	40
94	To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. *Trends in Pharmacological Sciences*, **2005**, 26, 517-25	13.2	152
93	Upregulation of A2A adenosine receptor expression by TNF-alpha in PBMC of patients with CHF: a regulatory mechanism of inflammation. *Journal of Cardiac Failure*, **2005**, 11, 67-73	3.3	34
92	CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. *Biochemical Pharmacology*, **2005**, 71, 115-25	6	54

91	Resistance of human astrocytoma cells to apoptosis induced by mitochondria-damaging agents: possible implications for anticancer therapy. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 314, 825-37	4.7	24
90	CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation. *Journal of Cell Science*, **2005**, 118, 5625-36	5.3	53
89	Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 308, 838-45	4.7	185
88	Regulation of A2B adenosine receptor functioning by tumour necrosis factor a in human astroglial cells. *Journal of Neurochemistry*, **2004**, 91, 1180-90	6	59
87	Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) receptor. *Biochemical Pharmacology*, **2004**, 68, 113-24	6	101
86	Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. *Biochemical Pharmacology*, **2004**, 68, 125-34	6	81
85	Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. *Glia*, **2003**, 43, 190-4	9	112
84	Nucleotide-mediated calcium signaling in rat cortical astrocytes: Role of P2X and P2Y receptors. *Glia*, **2003**, 43, 218-03	9	205
83	Intracellular phosphorylation of chloro-adenosine analogs is a prerequisite for activation of caspase-3 and induction of apoptosis in human astrocytoma cells. *Drug Development Research*, **2003** , 58, 396-404	5.1	3
82	P2Y receptors in brain astroglial cells: Identification of a gliotic P2Y receptor coupled to activation of a calcium-independent ras/ERK1/2 pathway. *Drug Development Research*, **2003**, 59, 161-170	5.1	7
81	Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. *Trends in Pharmacological Sciences*, **2003**, 24, 52-5	13.2	351
80	Changes of peripheral A2A adenosine receptors in chronic heart failure and cardiac transplantation. *FASEB Journal*, **2003**, 17, 280-2	0.9	76
79	Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. *FASEB Journal*, **2003**, 17, 2148-50	0.9	69
78	A key role for caspase-2 and caspase-3 in the apoptosis induced by 2-chloro-2'-deoxy-adenosine (cladribine) and 2-chloro-adenosine in human astrocytoma cells. *Molecular Pharmacology*, **2003**, 63, 1437-47	4.3	39
77	Induction of COX-2 and reactive gliosis by P2Y receptors in rat cortical astrocytes is dependent on ERK1/2 but independent of calcium signalling. *Journal of Neurochemistry*, **2002**, 83, 1285-96	6	68
76	A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation. *Molecular Pharmacology*, **2002**, 62, 1373-84	4.3	62
75	Enhanced apoptosis of peripheral blood mononuclear cells in cardiac transplanted patients undergoing chronic immunosuppressive treatment. *Transplant Immunology*, **2002**, 10, 269-75	1.7	3
74	Modulation of cyclooxygenase-2 and brain reactive astrogliosis by purinergic P2 receptors. *Annals of the New York Academy of Sciences*, **2001**, 939, 54-62	6.5	36

73	The A3 adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteins. *Annals of the New York Academy of Sciences*, **2001**, 939, 63-73	6.5	26
72	Two distinct P2Y receptors are involved in purine- and pyrimidine-evoked Ca2+ elevation in mammalian brain astrocytic cultures. *Drug Development Research*, **2001**, 52, 122-132	5.1	4
71	Identification of a novel P2 receptor associated with cyclooxygenase-2 upregulation and reactive astrogliosis. *Drug Development Research*, **2001**, 53, 148-157	5.1	2
70	Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin. *FASEB Journal*, **2001**, 15, 1245-1247	0.9	82
69	Apoptosis induced by 2-chloro-adenosine and 2-chloro-2Qdeoxy-adenosine in a human astrocytoma cell line: differential mechanisms and possible clinical relevance. *Journal of Neuroscience Research*, **2000**, 60, 388-400	4.4	38
68	Activation of the A3 adenosine receptor affects cell cycle progression and cell growth. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2000**, 361, 225-34	3.4	70
67	2-Chloro-adenosine induces a glutamate-dependent calcium response in C2C12 myotubes. *Biochemical and Biophysical Research Communications*, **2000**, 277, 546-51	3.4	3
66	Adenosine, the imperfect endogenous anti-ischemic cardio-neuroprotector. *Brain Research Bulletin*, **2000**, 52, 75-82	3.9	37
65	Adenosine- and 2-chloro-adenosine-induced cytopathic effects on myoblastic cells and myotubes: involvement of different intracellular mechanisms. *Neuromuscular Disorders*, **2000**, 10, 436-46	2.9	19
64	A novel gliotic P2 receptor mediating cyclooxygenase-2 induction in rat and human astrocytes. *Journal of the Autonomic Nervous System*, **2000**, 81, 3-9		28
63	Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. *Annals of the New York Academy of Sciences*, **1999**, 890, 79-92	6.5	78
62	Cyclo-oxygenase-2 mediates P2Y receptor-induced reactive astrogliosis. *British Journal of Pharmacology*, **1999**, 126, 563-7	8.6	67
61	Adenosine-induced cell death: evidence for receptor-mediated signalling. *Apoptosis: an International Journal on Programmed Cell Death*, **1999**, 4, 197-211	5.4	88
60	Disclosing apoptosis in the CNS. *Trends in Pharmacological Sciences*, **1999**, 20, 129-31	13.2	1
59	Signalling mechanisms involved in P2Y receptor-mediated reactive astrogliosis. *Progress in Brain Research*, **1999**, 120, 333-42	2.9	31
58	Activation and Desensitization of Rat A-Adenosine Receptors by Selective Adenosine Derivatives and Xanthine-7-Ribosides. *Drug Development Research*, **1998**, 44, 97-105	5.1	12
57	Adenosine A3 receptors and viability of astrocytes **1998**, 45, 379-386		38
56	European Stroke Prevention Study-2 results: serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation?. *Trends in Pharmacological Sciences*, **1998**, 19, 14-6	13.2	36

55	Apoptosis by 2-chloro-2Qdeoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. *Neurochemistry International*, **1998**, 32, 493-504	4.4	69
54	Purinergic signalling: pathophysiological roles. *The Japanese Journal of Pharmacology*, **1998**, 78, 113-45		345
53	Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. *Biochemical and Biophysical Research Communications*, **1997**, 232, 317-22	3.4	94
52	Actin cytoskeleton as a target for 2-chloro adenosine: evidence for induction of apoptosis in C2C12 myoblastic cells. *Biochemical and Biophysical Research Communications*, **1997**, 238, 361-6	3.4	11
51	The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. *Biochemical and Biophysical Research Communications*, **1997**, 241, 297-304	3.4	79
50	Towards a revised nomenclature for P1 and P2 receptors. *Trends in Pharmacological Sciences*, **1997**, 18, 79-82	13.2	265
49	Modulation of apoptosis by adenosine in the central nervous system: a possible role for the A3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders. *Annals of the New York Academy of Sciences*, **1997**, 825, 11-22	6.5	72
48	Characterization of the Ca2+ responses evoked by ATP and other nucleotides in mammalian brain astrocytes. *British Journal of Pharmacology*, **1997**, 121, 1700-6	8.6	73
47	Characterization of the signalling pathways involved in ATP and basic fibroblast growth factor-induced astrogliosis. *British Journal of Pharmacology*, **1997**, 121, 1692-9	8.6	78
46	Adenosine A3 receptor agonist-induced neurotoxicity in rat cerebellar granule neurons **1997**, 40, 267-273		37
45	Different pathways of apoptosis revealed by 2-chloro-adenosine and deoxy-D-ribose in mammalian astroglial cells. *Journal of Neuroscience Research*, **1997**, 47, 372-83	4.4	43
44	Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. *Trends in Neurosciences*, **1996**, 19, 13-8	13.3	392
43	Purinoceptors in the central nervous system **1996**, 39, 361-370		6
42	P1 and P2 receptors in cell growth and differentiation **1996**, 39, 393-406		41
41	Purines and cell death **1996**, 39, 442-449		27
40	Trophic roles of P2 purinoceptors in central nervous system astroglial cells. *Novartis Foundation Symposium*, **1996**, 198, 142-7; discussion 147-8		7
39	Effects of ATP analogues and basic fibroblast growth factor on astroglial cell differentiation in primary cultures of rat striatum. *International Journal of Developmental Neuroscience*, **1995**, 13, 685-93	2.7	56
38	A novel action for adenosine: apoptosis of astroglial cells in rat brain primary cultures. *Biochemical and Biophysical Research Communications*, **1995**, 213, 908-15	3.4	79

37	Adenosine A1 receptors in rat brain synaptosomes: Transductional mechanisms, effects on glutamate release, and preservation after metabolic inhibition. *Drug Development Research*, **1995**, 35, 119-129	5.1	4
36	Purinoceptors on Glial Cells of the Central Nervous System: Functional and Pathologic Implications **1995**, 271-280		10
35	Purinoceptors: are there families of P2X and P2Y purinoceptors? **1994**, 64, 445-75		919
34	Modulation of astroglial cell proliferation by analogues of adenosine and ATP in primary cultures of rat striatum. *Neuroscience*, **1994**, 59, 67-76	3.9	130
33	Purinoceptor nomenclature: A status report. *Drug Development Research*, **1993**, 28, 207-213	5.1	80
32	Adenosine receptors in rat brain synaptosomes: Receptor characterization and relationships with glutamate release. *Drug Development Research*, **1993**, 28, 359-363	5.1	2
31	Prolonged agonist exposure induces imbalance of A1 and A2 receptor-mediated functions in rat brain slices. *Drug Development Research*, **1993**, 28, 364-368	5.1	9
30	Synthesis and pharmacological characterization of 2-(4-chloro-3-hydroxyphenyl)ethylamine and N,N-dialkyl derivatives as dopamine receptor ligands. *Journal of Medicinal Chemistry*, **1992**, 35, 4408-14	8.3	17
29	Adenosine receptors in rat basophilic leukaemia cells: transductional mechanisms and effects on 5-hydroxytryptamine release. *British Journal of Pharmacology*, **1992**, 105, 405-11	8.6	9
28	G-proteins and diabetic encephalopathy: molecular mechanisms underlying the functional alterations. *Pharmacological Research*, **1992**, 25 Suppl 1, 109-10	10.2	
27	Prolonged in vitro exposure of rat brain slices to adenosine analogues: selective desensitization of adenosine A1 but not A2 receptors. *European Journal of Pharmacology*, **1992**, 227, 317-24		56
26	Diabetes-induced alterations of central nervous system G proteins. ADP-ribosylation, immunoreactivity, and gene-expression studies in rat striatum. *Molecular and Chemical Neuropathology*, **1992**, 17, 259-72		12
25	Early alterations of Gi/Go protein-dependent transductional processes in the retina of diabetic animals. *Journal of Neuroscience Research*, **1991**, 29, 196-200	4.4	10
24	Adrenergic-prostaglandin interactions in the respiratory system. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **1990**, 40, 85-91	2.8	3
23	Beta-adrenoceptor desensitization induced by antigen challenge in guinea-pig trachea. *European Journal of Pharmacology*, **1990**, 178, 21-7	5.3	3
22	Response: behavioral teratology: what's not in a name. *Neurotoxicology and Teratology*, **1989**, 11, 329	3.9	
21	In vivo modulation of striatal phosphoproteins by dopaminergic agents. *European Journal of Pharmacology*, **1989**, 172, 321-8		5
20	Denervation and hyperinnervation in the nervous system of diabetic animals. II. Monoaminergic and peptidergic alterations in the diabetic encephalopathy. *Journal of Neuroscience Research*, **1989**, 24, 362-8	4.4	33

19	Denervation and hyperinnervation in the nervous system of diabetic animals: III. Functional alterations of G proteins in diabetic encephalopathy. *Journal of Neuroscience Research*, **1989**, 24, 517-23	4.4	26
18	Methylazoxymethanol-induced microencephaly: persistent increase of cortical somatostatin-like immunoreactivity. *Developmental Brain Research*, **1989**, 47, 156-9		15
17	Adenosine receptors linked to adenylate cyclase activity in human neuroblastoma cells: modulation during cell differentiation. *Neuroscience*, **1989**, 30, 819-25	3.9	34
16	Behavioral teratology: an inappropriate term for some uninterpretable effects. *Trends in Pharmacological Sciences*, **1988**, 9, 13-5	13.2	14
15	Adenosine modulates the dopaminergic function in the nigro-striatal system by interacting with striatal dopamine dependent adenylate cyclase. *Pharmacological Research Communications*, **1987**, 19, 275-86		22
14	Selective activity of bamifylline on adenosine A1-receptors in rat brain. *Pharmacological Research Communications*, **1987**, 19, 537-45		13
13	Functional and biochemical modifications of lung beta-adrenoreceptors after in vivo desensitization: prevention by indomethacin. *Autonomic and Autacoid Pharmacology*, **1986**, 6, 47-51		5
12	Arachidonic acid metabolites and lung beta-adrenoceptor desensitization. *Pharmacological Research Communications*, **1986**, 18, 93-110		11
11	Arachidonic acid metabolites induce beta-adrenoceptor desensitization in rat lung in vitro. *Prostaglandins*, **1985**, 30, 799-809		9
10	Involvement of arachidonic acid metabolites in beta-adrenoceptor desensitization: functional and biochemical studies. *European Journal of Pharmacology*, **1984**, 106, 601-6	5.3	15
9	Beta-adrenoceptor desensitization in rat lung: functional and biochemical aspects. *European Journal of Pharmacology*, **1983**, 89, 35-42	5.3	11
8	The phagocytosis and transforming activity of crystalline metal sulfide particles are related to their negative surface charge. *Carcinogenesis*, **1982**, 3, 175-80	4.6	54
7	Cytoplasmic dissolution of phagocytized crystalline nickel sulfide particles: a prerequisite for nuclear uptake of nickel. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **1982**, 9, 663-76	3.2	35
6	The regulation of ionic nickel uptake and cytotoxicity by specific amino acids and serum components. *Biological Trace Element Research*, **1982**, 4, 289-301	4.5	32
5	Cellular effects of ornithine decarboxylase induction in cells maintained with a salts/glucose medium. *Life Sciences*, **1981**, 28, 937-44	6.8	2
4	Differences in surface properties of amorphous and crystalline metal sulfides may explain their toxicological potency. *Chemosphere*, **1981**, 10, 897-908	8.4	14
3	Factors influencing the phagocytosis, neoplastic transformation, and cytotoxicity of particulate nickel compounds in tissue culture systems. *Toxicology and Applied Pharmacology*, **1981**, 60, 313-23	4.6	70
2	Functional genomic analyses highlights a shift in Gpr17-regulated cellular processes in oligodendrocyte progenitor cells (OPC) and underlying myelin dysregulation in the aged forebrain		1

List of Publications

1 Pathophysiological Roles of P2 Receptors in Glial Cells. *Novartis Foundation Symposium*,91-106 27